Scherrer Jeffrey F, Salas Joanne, Lustman Patrick J, Burge Sandra, Schneider F David
Department of Family and Community Medicine, Saint Louis University School of Medicine, St Louis, MO, USA Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA The Bell Street Clinic, John Cochran Hospital, St Louis, MO, USA Department of Family and Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Pain. 2015 Feb;156(2):348-355. doi: 10.1097/01.j.pain.0000460316.58110.a0.
Depression is associated with receipt of higher doses of prescription opioids. It is not known whether the reverse association exists in that an increased opioid dose is associated with increased depression. Questionnaires were administered to 355 patients with chronic low back pain at baseline and 1-year and 2-year follow-up. Depression, pain, anxiety, health-related quality of life, and social support or stress were obtained by survey. Opioid type and dose and comorbid conditions were derived from chart abstraction. Random intercept, generalized linear mixed models were computed to estimate the association between change in opioid morphine equivalent dose (MED) thresholds (0, 1-50, >50 mg) and probability of depression over time. Second, we computed the association between change in depression and odds of an increasing MED over time. After adjusting for covariates, an increase to >50 mg MED from nonuse increased a participant's probability of depression over time (odds ratio [OR] = 2.65; 95% confidence interval [CI], 1.17-5.98). An increase to 1 to 50 mg MED did not increase an individual's probability of depression over time (OR = 1.08; 95% CI, 0.65-1.79). In unadjusted analysis, developing depression was associated with a 2.13 (95% CI, 1.36-3.36) increased odds of a higher MED. This association decreased after adjusting for all covariates (OR = 1.65; 95% CI, 0.97-2.81). Post hoc analysis revealed that depression was significantly associated with a 10.1-mg MED increase in fully adjusted models. Change to a higher MED leads to an increased risk of depression, and developing depression increases the likelihood of a higher MED. We speculate that treating depression or lowering MED may mitigate a bidirectional association and ultimately improve pain management.
抑郁症与接受更高剂量的处方阿片类药物有关。尚不清楚是否存在相反的关联,即阿片类药物剂量增加是否与抑郁症增加有关。在基线、1年和2年随访时,对355例慢性腰痛患者进行问卷调查。通过调查获取抑郁症、疼痛、焦虑、健康相关生活质量以及社会支持或压力情况。阿片类药物类型、剂量和共病情况来自病历摘要。计算随机截距广义线性混合模型,以估计阿片类药物吗啡等效剂量(MED)阈值变化(0、1 - 50、>50毫克)与随时间发生抑郁症的概率之间的关联。其次,我们计算了抑郁症变化与随时间MED增加的几率之间的关联。在调整协变量后,从未使用增加到MED>50毫克会增加参与者随时间发生抑郁症的概率(优势比[OR]=2.65;95%置信区间[CI],1.17 - 5.98)。增加到MED 1至50毫克不会增加个体随时间发生抑郁症的概率(OR = 1.08;95% CI,0.65 - 1.79)。在未调整分析中,发生抑郁症与MED升高的几率增加2.13(95% CI,1.36 - 3.36)有关。在调整所有协变量后,这种关联降低(OR = 1.65;95% CI,0.97 - 2.81)。事后分析显示,在完全调整模型中,抑郁症与MED增加10.1毫克显著相关。MED升高会导致抑郁症风险增加,而发生抑郁症会增加MED升高的可能性。我们推测,治疗抑郁症或降低MED可能会减轻双向关联,并最终改善疼痛管理。